SlideShare a Scribd company logo
FORMAT &
SUBMISSION
OF ACTD
BY PRACHI SHARMA
M. Pharm. DRA
(I Sem)
CONTENTS
• ACTD
• ASEAN Countries
• ACTD Objective
• ASEAN Applications
• Parts of ACTD
• Format of ACTD
• Conclusion
ACTD
ACTD is ASEAN Common Technical Document.
This ASEAN Common Technical Dossier (ACTD) is a guideline of the
agreed-upon common format for the preparation of a well-structured
Common Technical Dossier (CTD) application which was submitted to
ASEAN regulatory authorities for the registration of pharmaceuticals for
human use.
ASEAN is a CTD document for South East Asian Countries. A bunch of
10 countries came together to lay down their own rules and regulations
for dossier submission.
ASEAN Countries
A bunch of 10 countries came together to join hands and lay down their own rules and
regulations for dossier submission.
List of 10 ASEAN Countries:
1. Laos
2. Burma (Myanmar)
3. Brunei
4. Cambodia
5. Malaysia
6. Singapore
7. Thailand
8. Phillippines
9. Vietnam
10. Indonesia
ACTD Objective
• To develop the harmonization scheme of Pharmaceuticals regulations
of the ASEAN member countries, to complement and facilitate the
objectives of ASEAN Free Trade Area, particularly the elimination of
Technical Barriers to Trade posed by the regulations, without
compromising on drug quality, efficacy and safety.
ACTD Applications
ASEAN countries came together to simplify the trade and approval
procedures for the drug products o be introduced in the market. The
countries pay low excise and levy duties to trade their products in the
ASEAN markets.
Hence, ACTD has following applications;
• For registration of pharmaceutical products in local market
• For registration of pharmaceutical product in international market
• For renewal of registration of pharmaceutical product
ACTD Format
The ACTD consists of four parts. These four parts contain all the information
required by the regulatory agencies to be submitted by the applicant.
Part 1: Table of Content, Administrative Data and Product Information:
This part contains all the relevant information regarding the whole ACTD to
provide basis details. A general introduction to the pharmaceutical product,
its class, mode of action, etc.
Part 2: Quality Document:
This part provides the overall summary and the study reports.
Part 3: Non-Clinical Document:
Part III provides the non-clinical overview, written summaries and
tabulated summaries. But for ASEAN countries, these study reports
may not be required for Major Variation Products if the original product
is already registered and approved in Reference Countries.
Part 4: Clinical Document:
Part IV provides the Clinical overview and clinical summary. This
document is not needed for generic products.
Part 1: Table of Content, Adminisrative Data and Prescribing
Information
Section A: Introduction
Section B: Table of Contents
Section C: Documents required for registration
Part 2: Quality Documents:
Section A: Table of Contents
Section B: Quality Overall Summary
Section C: Body of Data
Part 3: Non-Clinical document
Section A: table of Contents
Section B: Non-Clinical Overview
Section C: Non-Clinical Written and Tabulated Summary
1. Table of Contents
2. Pharmacology
3. Pharmacokinetics
4. Toxicology
Section D: Non-Clinical Study Reports
1. Table of Contents
2. Pharmacology
3. Pharmacokinetics
4. Toxicology
Part 4: Clinical Document
Section A: Table of Contents
Section B: Clinical Overview
Section C: Clinical Summary
1. Summary of Biopharmaceutics and Associated Analytical Methods
2. Summary of Clinical Pharmacology Studies
3. Summary of Clinical Efficacy
4. Summary of Clinical Safety
5. Synopses of Individual Studies
Section D: Tabular Listing of all Clinical Studies
Section E: Clinical Study Reports
Section F: List of Key Literature References
Conclusion
ACTD is a guideline for the preparation of well-structured CTD
applications that would be submitted to ASEAN regulatory authorities
for the registration pf pharmaceuticals for human use.
ACTD has an advantage that it can be use for the whole region instead
of a particular country. This harmonized format of ACTD facilitates the
regulatiry review.

More Related Content

What's hot

Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
Swapnil Fernandes
 
Code of Federal Regulations
Code of Federal RegulationsCode of Federal Regulations
Code of Federal Regulations
Swapnil Fernandes
 
2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.
Audumbar Mali
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
Dr Sukanta sen
 
Clinical trial protocol development
Clinical trial protocol developmentClinical trial protocol development
Clinical trial protocol development
SACHIN C P
 
NEW DRUG APPLICATION (NDA).pptx
NEW DRUG APPLICATION (NDA).pptxNEW DRUG APPLICATION (NDA).pptx
NEW DRUG APPLICATION (NDA).pptx
AmitSahu546305
 
Orange book
Orange bookOrange book
Orange book
Rucha Pathak
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
Audumbar Mali
 
eCTD
eCTDeCTD
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIAA REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
International Journal of Drug Regulatory Affairs
 
New drug application
New drug applicationNew drug application
New drug applicationVKEkbote
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
Dr. Ramesh Bhandari
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European Union
Doninder Hooda
 
overview of Japan pharmaceutical regulatory authority - PMDA
overview of Japan  pharmaceutical regulatory authority - PMDAoverview of Japan  pharmaceutical regulatory authority - PMDA
overview of Japan pharmaceutical regulatory authority - PMDA
Nandhanan
 
FORMAT & SUBMISSION.pptx
FORMAT & SUBMISSION.pptxFORMAT & SUBMISSION.pptx
FORMAT & SUBMISSION.pptx
PrachiSharma575050
 
Drug Master File submissions
Drug Master File submissionsDrug Master File submissions
Drug Master File submissions
Arshad Khan
 
NEW DRUG APPLICATION
NEW DRUG APPLICATIONNEW DRUG APPLICATION
NEW DRUG APPLICATION
SACHIN C P
 
The relevance of the Purple Book for current debates
The relevance of the Purple Book for current debatesThe relevance of the Purple Book for current debates
The relevance of the Purple Book for current debates
THL
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or anda
Gaurav Sharma
 

What's hot (20)

Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
 
Code of Federal Regulations
Code of Federal RegulationsCode of Federal Regulations
Code of Federal Regulations
 
2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
 
Clinical trial protocol development
Clinical trial protocol developmentClinical trial protocol development
Clinical trial protocol development
 
NEW DRUG APPLICATION (NDA).pptx
NEW DRUG APPLICATION (NDA).pptxNEW DRUG APPLICATION (NDA).pptx
NEW DRUG APPLICATION (NDA).pptx
 
Orange book
Orange bookOrange book
Orange book
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
 
eCTD
eCTDeCTD
eCTD
 
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIAA REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
 
New drug application
New drug applicationNew drug application
New drug application
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European Union
 
overview of Japan pharmaceutical regulatory authority - PMDA
overview of Japan  pharmaceutical regulatory authority - PMDAoverview of Japan  pharmaceutical regulatory authority - PMDA
overview of Japan pharmaceutical regulatory authority - PMDA
 
FORMAT & SUBMISSION.pptx
FORMAT & SUBMISSION.pptxFORMAT & SUBMISSION.pptx
FORMAT & SUBMISSION.pptx
 
Drug Master File submissions
Drug Master File submissionsDrug Master File submissions
Drug Master File submissions
 
Anda
AndaAnda
Anda
 
NEW DRUG APPLICATION
NEW DRUG APPLICATIONNEW DRUG APPLICATION
NEW DRUG APPLICATION
 
The relevance of the Purple Book for current debates
The relevance of the Purple Book for current debatesThe relevance of the Purple Book for current debates
The relevance of the Purple Book for current debates
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or anda
 

Similar to FORMAT & SUBMISSION.pptx

Dossier format and filing.pptx
Dossier format and filing.pptxDossier format and filing.pptx
Dossier format and filing.pptx
PrachiSharma575050
 
Dossier format and filing.pptx
Dossier format and filing.pptxDossier format and filing.pptx
Dossier format and filing.pptx
PrachiSharma575050
 
Regulatory Affairs role in Pharmaceutical Industry
Regulatory Affairs role in Pharmaceutical IndustryRegulatory Affairs role in Pharmaceutical Industry
Regulatory Affairs role in Pharmaceutical Industry
Tarun Kumar Reddy
 
ASEAN COUNTRIES.pptx
ASEAN COUNTRIES.pptxASEAN COUNTRIES.pptx
ASEAN COUNTRIES.pptx
AartiVats5
 
Common technical document format
Common technical document formatCommon technical document format
Common technical document format
Dev Jain
 
CTD & ectd.pptx
CTD & ectd.pptxCTD & ectd.pptx
CTD & ectd.pptx
RizwanAhmad812370
 
CTD and eCTD.pptx
CTD and eCTD.pptxCTD and eCTD.pptx
CTD and eCTD.pptx
GauravPanchal55
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
Vikas Rathee
 
CTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory AffairsCTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory Affairs
Dipesh Gosavi
 
Regulatory submission in Japan
Regulatory submission in JapanRegulatory submission in Japan
Regulatory submission in Japan
Rohit Patil
 
CTD structure
CTD structureCTD structure
CTD structure
Chandra Mohan
 
Registration of Indian Drug Product in Overseas Market.pptx
Registration of Indian Drug Product in Overseas Market.pptxRegistration of Indian Drug Product in Overseas Market.pptx
Registration of Indian Drug Product in Overseas Market.pptx
Nipun Gupta
 
Ctd and e ctd
Ctd and e ctdCtd and e ctd
Ctd and e ctd
Sayeda Salma S.A.
 
CTD.pptx
CTD.pptxCTD.pptx
CTD.pptx
Sunshine584665
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
Tanmay Madhavi
 
NDA.pptx
NDA.pptxNDA.pptx
NDA.pptx
MansiChauhan98
 
NDA.pptx
NDA.pptxNDA.pptx
NDA.pptx
MansiChauhan97
 
ICH GUIDELINES
ICH GUIDELINESICH GUIDELINES
ICH GUIDELINES
BishalBhattacharjee11
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
Bindu Kshtriya
 
121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx
TridevSastri1
 

Similar to FORMAT & SUBMISSION.pptx (20)

Dossier format and filing.pptx
Dossier format and filing.pptxDossier format and filing.pptx
Dossier format and filing.pptx
 
Dossier format and filing.pptx
Dossier format and filing.pptxDossier format and filing.pptx
Dossier format and filing.pptx
 
Regulatory Affairs role in Pharmaceutical Industry
Regulatory Affairs role in Pharmaceutical IndustryRegulatory Affairs role in Pharmaceutical Industry
Regulatory Affairs role in Pharmaceutical Industry
 
ASEAN COUNTRIES.pptx
ASEAN COUNTRIES.pptxASEAN COUNTRIES.pptx
ASEAN COUNTRIES.pptx
 
Common technical document format
Common technical document formatCommon technical document format
Common technical document format
 
CTD & ectd.pptx
CTD & ectd.pptxCTD & ectd.pptx
CTD & ectd.pptx
 
CTD and eCTD.pptx
CTD and eCTD.pptxCTD and eCTD.pptx
CTD and eCTD.pptx
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
 
CTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory AffairsCTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory Affairs
 
Regulatory submission in Japan
Regulatory submission in JapanRegulatory submission in Japan
Regulatory submission in Japan
 
CTD structure
CTD structureCTD structure
CTD structure
 
Registration of Indian Drug Product in Overseas Market.pptx
Registration of Indian Drug Product in Overseas Market.pptxRegistration of Indian Drug Product in Overseas Market.pptx
Registration of Indian Drug Product in Overseas Market.pptx
 
Ctd and e ctd
Ctd and e ctdCtd and e ctd
Ctd and e ctd
 
CTD.pptx
CTD.pptxCTD.pptx
CTD.pptx
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
 
NDA.pptx
NDA.pptxNDA.pptx
NDA.pptx
 
NDA.pptx
NDA.pptxNDA.pptx
NDA.pptx
 
ICH GUIDELINES
ICH GUIDELINESICH GUIDELINES
ICH GUIDELINES
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
 
121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx
 

More from PrachiSharma575050

rahb module 5.pptx
rahb module 5.pptxrahb module 5.pptx
rahb module 5.pptx
PrachiSharma575050
 
ISO 13485.pptx
ISO 13485.pptxISO 13485.pptx
ISO 13485.pptx
PrachiSharma575050
 
21 CFR Part 11.pptx
21 CFR Part 11.pptx21 CFR Part 11.pptx
21 CFR Part 11.pptx
PrachiSharma575050
 
EUROPEAN MEDICINE AGENCY.pptx
EUROPEAN MEDICINE AGENCY.pptxEUROPEAN MEDICINE AGENCY.pptx
EUROPEAN MEDICINE AGENCY.pptx
PrachiSharma575050
 
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptxINVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
PrachiSharma575050
 
21 CFR Part 11.pptx
21 CFR Part 11.pptx21 CFR Part 11.pptx
21 CFR Part 11.pptx
PrachiSharma575050
 
Post Marketing Survelliance.pptx
Post Marketing Survelliance.pptxPost Marketing Survelliance.pptx
Post Marketing Survelliance.pptx
PrachiSharma575050
 

More from PrachiSharma575050 (7)

rahb module 5.pptx
rahb module 5.pptxrahb module 5.pptx
rahb module 5.pptx
 
ISO 13485.pptx
ISO 13485.pptxISO 13485.pptx
ISO 13485.pptx
 
21 CFR Part 11.pptx
21 CFR Part 11.pptx21 CFR Part 11.pptx
21 CFR Part 11.pptx
 
EUROPEAN MEDICINE AGENCY.pptx
EUROPEAN MEDICINE AGENCY.pptxEUROPEAN MEDICINE AGENCY.pptx
EUROPEAN MEDICINE AGENCY.pptx
 
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptxINVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
 
21 CFR Part 11.pptx
21 CFR Part 11.pptx21 CFR Part 11.pptx
21 CFR Part 11.pptx
 
Post Marketing Survelliance.pptx
Post Marketing Survelliance.pptxPost Marketing Survelliance.pptx
Post Marketing Survelliance.pptx
 

Recently uploaded

Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
Wasim Ak
 
How to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP ModuleHow to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP Module
Celine George
 
What is the purpose of studying mathematics.pptx
What is the purpose of studying mathematics.pptxWhat is the purpose of studying mathematics.pptx
What is the purpose of studying mathematics.pptx
christianmathematics
 
Reflective and Evaluative Practice...pdf
Reflective and Evaluative Practice...pdfReflective and Evaluative Practice...pdf
Reflective and Evaluative Practice...pdf
amberjdewit93
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Dr. Vinod Kumar Kanvaria
 
Digital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments UnitDigital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments Unit
chanes7
 
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
Ashish Kohli
 
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat  Leveraging AI for Diversity, Equity, and InclusionExecutive Directors Chat  Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
TechSoup
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
amberjdewit93
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
goswamiyash170123
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
tarandeep35
 
Fresher’s Quiz 2023 at GMC Nizamabad.pptx
Fresher’s Quiz 2023 at GMC Nizamabad.pptxFresher’s Quiz 2023 at GMC Nizamabad.pptx
Fresher’s Quiz 2023 at GMC Nizamabad.pptx
SriSurya50
 
PIMS Job Advertisement 2024.pdf Islamabad
PIMS Job Advertisement 2024.pdf IslamabadPIMS Job Advertisement 2024.pdf Islamabad
PIMS Job Advertisement 2024.pdf Islamabad
AyyanKhan40
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
thanhdowork
 
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdfবাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
eBook.com.bd (প্রয়োজনীয় বাংলা বই)
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
NelTorrente
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 

Recently uploaded (20)

Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
 
How to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP ModuleHow to Add Chatter in the odoo 17 ERP Module
How to Add Chatter in the odoo 17 ERP Module
 
What is the purpose of studying mathematics.pptx
What is the purpose of studying mathematics.pptxWhat is the purpose of studying mathematics.pptx
What is the purpose of studying mathematics.pptx
 
Reflective and Evaluative Practice...pdf
Reflective and Evaluative Practice...pdfReflective and Evaluative Practice...pdf
Reflective and Evaluative Practice...pdf
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
 
Digital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments UnitDigital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments Unit
 
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
Aficamten in HCM (SEQUOIA HCM TRIAL 2024)
 
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat  Leveraging AI for Diversity, Equity, and InclusionExecutive Directors Chat  Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
 
Fresher’s Quiz 2023 at GMC Nizamabad.pptx
Fresher’s Quiz 2023 at GMC Nizamabad.pptxFresher’s Quiz 2023 at GMC Nizamabad.pptx
Fresher’s Quiz 2023 at GMC Nizamabad.pptx
 
PIMS Job Advertisement 2024.pdf Islamabad
PIMS Job Advertisement 2024.pdf IslamabadPIMS Job Advertisement 2024.pdf Islamabad
PIMS Job Advertisement 2024.pdf Islamabad
 
A Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptxA Survey of Techniques for Maximizing LLM Performance.pptx
A Survey of Techniques for Maximizing LLM Performance.pptx
 
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdfবাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 

FORMAT & SUBMISSION.pptx

  • 1. FORMAT & SUBMISSION OF ACTD BY PRACHI SHARMA M. Pharm. DRA (I Sem)
  • 2. CONTENTS • ACTD • ASEAN Countries • ACTD Objective • ASEAN Applications • Parts of ACTD • Format of ACTD • Conclusion
  • 3. ACTD ACTD is ASEAN Common Technical Document. This ASEAN Common Technical Dossier (ACTD) is a guideline of the agreed-upon common format for the preparation of a well-structured Common Technical Dossier (CTD) application which was submitted to ASEAN regulatory authorities for the registration of pharmaceuticals for human use. ASEAN is a CTD document for South East Asian Countries. A bunch of 10 countries came together to lay down their own rules and regulations for dossier submission.
  • 4. ASEAN Countries A bunch of 10 countries came together to join hands and lay down their own rules and regulations for dossier submission. List of 10 ASEAN Countries: 1. Laos 2. Burma (Myanmar) 3. Brunei 4. Cambodia 5. Malaysia 6. Singapore 7. Thailand 8. Phillippines 9. Vietnam 10. Indonesia
  • 5. ACTD Objective • To develop the harmonization scheme of Pharmaceuticals regulations of the ASEAN member countries, to complement and facilitate the objectives of ASEAN Free Trade Area, particularly the elimination of Technical Barriers to Trade posed by the regulations, without compromising on drug quality, efficacy and safety.
  • 6. ACTD Applications ASEAN countries came together to simplify the trade and approval procedures for the drug products o be introduced in the market. The countries pay low excise and levy duties to trade their products in the ASEAN markets. Hence, ACTD has following applications; • For registration of pharmaceutical products in local market • For registration of pharmaceutical product in international market • For renewal of registration of pharmaceutical product
  • 7. ACTD Format The ACTD consists of four parts. These four parts contain all the information required by the regulatory agencies to be submitted by the applicant. Part 1: Table of Content, Administrative Data and Product Information: This part contains all the relevant information regarding the whole ACTD to provide basis details. A general introduction to the pharmaceutical product, its class, mode of action, etc. Part 2: Quality Document: This part provides the overall summary and the study reports.
  • 8. Part 3: Non-Clinical Document: Part III provides the non-clinical overview, written summaries and tabulated summaries. But for ASEAN countries, these study reports may not be required for Major Variation Products if the original product is already registered and approved in Reference Countries. Part 4: Clinical Document: Part IV provides the Clinical overview and clinical summary. This document is not needed for generic products.
  • 9. Part 1: Table of Content, Adminisrative Data and Prescribing Information Section A: Introduction Section B: Table of Contents Section C: Documents required for registration Part 2: Quality Documents: Section A: Table of Contents Section B: Quality Overall Summary Section C: Body of Data
  • 10. Part 3: Non-Clinical document Section A: table of Contents Section B: Non-Clinical Overview Section C: Non-Clinical Written and Tabulated Summary 1. Table of Contents 2. Pharmacology 3. Pharmacokinetics 4. Toxicology Section D: Non-Clinical Study Reports 1. Table of Contents 2. Pharmacology 3. Pharmacokinetics 4. Toxicology
  • 11. Part 4: Clinical Document Section A: Table of Contents Section B: Clinical Overview Section C: Clinical Summary 1. Summary of Biopharmaceutics and Associated Analytical Methods 2. Summary of Clinical Pharmacology Studies 3. Summary of Clinical Efficacy 4. Summary of Clinical Safety 5. Synopses of Individual Studies Section D: Tabular Listing of all Clinical Studies Section E: Clinical Study Reports Section F: List of Key Literature References
  • 12. Conclusion ACTD is a guideline for the preparation of well-structured CTD applications that would be submitted to ASEAN regulatory authorities for the registration pf pharmaceuticals for human use. ACTD has an advantage that it can be use for the whole region instead of a particular country. This harmonized format of ACTD facilitates the regulatiry review.